Omeros (OMER) Stock Forecast & Price Target

Omeros is viewed favorably because YARTEMLEA has shown a strong early launch, with $28.5M in 2Q sales, 74 unique ordering accounts by 2Q, and about 75% of orders coming from adults, suggesting broad institutional uptake rather than a narrow pilot launch. The company’s upside is further supported by reimbursement tailwinds, since the permanent J-code went live July 1 and NTAP begins October 1, while the U.S. opportunity alone is estimated around ~$400M in peak sales with minimal Europe contribution required. Competitive risk appears manageable because YARTEMLEA holds first-approved, MASP-2 differentiated status in a severe high-risk population, and physician feedback supports more than 30% share over time, reinforcing the long-term commercial case.

Omeros is fundamentally challenged by its heavy near-term dependence on narsoplimab, making any regulatory setback or softer-than-forecast sales a direct threat to valuation and the path to profitability. The negative CHMP opinion in June and the still-ongoing formal re-examination leave Europe unresolved, while pipeline failures across OMS1029 and OMS527 would further reduce perceived franchise value. Even though U.S. investors may be more focused on YARTEMLEA dynamics and the Alexion/AZN data, the stock may remain range bound until 2Q26 earnings, reflecting unresolved approval risk, commercial uncertainty, and limited visibility on whether transplant centers will sustain first-line use.